Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche’s CNS Drug Pipeline Matures: More Investment, More Promise

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.

You may also be interested in...

Avastin Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions

The decision on whether Avastin’s metastatic breast cancer indication should be retained may come down to three words – “magnitude of benefit.”

Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients

Using a biomarker and investigational diagnostic, Roche has initiated a Phase II clinical trial of an amyloid-beta peptide antibody, gantenerumab, in patients with only mild cognitive deficits.

Alzheimer's Dx: An Essential Piece of the Puzzle

Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts